Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response

摘要

#$%^&*AU2020202827A120200521.pdf#####1003008204 Abstract of the disclosure The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.